PLEIOTROPIC EFFECTS OF GLP-1 RECEPTOR AGONISTS: A LITERATURE REVIEW
Authors:
- Wiktoria MarzecWMWiktoria Marzec
- Hanna MaruchniakHMHanna Maruchniak
- Paulina BiedrońPBPaulina Biedroń
- Anna SkrzypekASAnna Skrzypek
- Maciej HutkowskiMHMaciej Hutkowski
- Mikołaj ZbrożekMZMikołaj Zbrożek
- Zuzanna ChwostekZCZuzanna Chwostek
- Bartłomiej KosiarskiBKBartłomiej Kosiarski
- Patrycja MarkowiczPMPatrycja Markowicz
- Krzysztof BiłykKBKrzysztof Biłyk
Open Access
- 6 January 2026
- journal article
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been transformative in the management of type 2 diabetes (T2DM) and obesity. Advances in drug design have improved their bioavailability, allowing effective glucose control and weight loss with minimal side effects. Studies have demonstrated that GLP-1RAs, beyond their metabolic benefits, exert protective effects in multiple pathologies, including cardiovascular disease, liver disorders, kidney disease and neurodegeneration . Cardiovascular benefits include enhanced myocardial function, reduced atherosclerosis, improved endothelial health and a lower risk of major adverse cardiovascular events, alongside improved insulin sensitivity and lipid metabolism. In the liver, GLP-1RAs ameliorate metabolic dysfunction-associated steatotic liver disease by decreasing hepatic fat, inflammation and oxidative stress. In diabetic kidney disease, they exert renoprotective effects through anti-inflammatory, antioxidative and antihypertensive mechanisms. Emerging evidence also suggests neuropsychiatric benefits, including reductions in depressive and anxiety symptoms, decreased substance use and lower risk of Alzheimer’s, Parkinson’s and other dementias, likely mediated by modulation of neurotransmitter systems and neuroinflammation. This review summarizes preclinical and clinical evidence demonstrating the multifaceted effects of GLP-1RAs across multiple organ systems.Keywords
This publication has 30 references indexed in Scilit:
- Are Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative ReviewNeurology and Therapy, 2025
- Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trialsObesity Pillars, 2025
- Mapping the effectiveness and risks of GLP-1 receptor agonistsNature Medicine, 2025
- Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risksObesity Pillars, 2024
- Steatotic liver disease, MASLD and risk of chronic kidney diseaseDiabetes & Metabolism, 2023
- Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of actionNature Reviews Cardiology, 2023
- Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatmentPharmacological Research, 2022
- GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-artMolecular Metabolism, 2021
- Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeuticsMetabolism, 2019
- GLP‐1 receptor agonists: Nonglycemic clinical effects in weight loss and beyondObesity, 2015